Commercial Channels

Drug Channel’s analysis of Inc. 5000 shows some eye-popping growth

Mylan CEO sticks to authorized-generic strategy for price relief

Roche could overtake Novartis as the No. 1 global firm by then, says Evaluate Pharma

Pharmacy benefit managers feel some marketplace heat even as they establish new benefit programs

In first year, the product has six of Top 20 companies as clients

New study finds payer cost savings for patients with comorbidities

Zephyr Health adds Referral and Segment Analytics to its Illuminate data service

EpiPen controversy has a new twist: paying lower rebates to state Medicaid programs

Existing incentives continue to draw in new drug developers; payers begin to look at competitive markets to drive down drug costs

More unusual gyrations as Mylan attempts to quell uprising against its pricing policies

Good Neighbor and Health Mart franchises trade top positions

Presidential politicking adds momentum to the growing backlash, and not just for Mylan

Substantial investments have been made, but beneficial results hard to identify, says ZS Associates

Life sciences marketers contend with a flood of new data sources—and the challenge of integrating them for meaningful results

Applying specialty-pharma techniques to a potentially mass-market drug

Healthcare research firm calls out the alarmist predictions over PCSK9s and other new drugs

Advent joins Thomas Lee Partners in ownership of the clinical, commercial outsourcer

The scale of the cardiovascular market pushes payers to demand quality outcomes data

Bloomberg BusinessWeek rakes over charitable copay programs

Company pursues ‘bench to bedside’ commercialization services

Site opens up a Facebook-like “Pages” to vendors and medical organizations

Managed care organizations are adjusting rapidly to onslaught of specialty products

A raft of new therapies is generating renewed optimism for cancer care, but even as lower-cost biosimilars enter the market, cost is a crippling factor